•Novartis received European Commission approval for Itvisma, the first gene replacement therapy for a broad SMA population ranging from newborns to adults.
•Talos Energy announced pricing of an $800 million offering of 8.000% second-priority senior secured notes due 2034.
•The company plans to use proceeds to fund part of the cash consideration for its pending Gulf of America acquisition, redeem its 9.000% 2029 notes, and pay related fees and expenses.
